Evidence map›Paper›PMID 31082240›Full record

ArticleMolecular pharmaceutics2019

Ray R Zhang, Joseph J Grudzinksi, Tej I Mehta, Ronald R Burnette, Reinier Hernandez, Paul A Clark, Jonathan A Lubin, Anatoly N Pinchuk, Justin Jeffrey, Marc Longino and 2 more

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Next-generation agents for fluorescence-guided glioblastoma surgery.Bioengineering & translational medicine · 2024
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Joseph J Grudzinksi
Tej I Mehta
Ronald R Burnette
Reinier Hernandez
Paul A Clark
Jonathan A Lubin
Anatoly N PinchukCellectar Biosciences Inc. , Madison , Wisconsin , United States.
Justin Jeffrey
Marc LonginoCellectar Biosciences Inc. , Madison , Wisconsin , United States.
John S Kuo
Jamey P Weichert
University of Wisconsin–Madison · USCellectar Biosciences (United States) · US

Funding

INTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3M
Na-K-Cl cotransporter in Glioblastoma MultiformeR01NS075995 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUN, DANDAN · 2011 to 2015
$1.8M
PET/CT Imaging of Malignant Brain Tumors with 124I-NM404R01CA158800 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI HALL, LANCE T, WEICHERT, JAMEY P · 2011 to 2014
$1.2M
NCI NIH HHS R01 CA158800NIGMS NIH HHS T32 GM008692NINDS NIH HHS R01 NS075995
6 · The paper itself

Abstract

Alkylphosphocholine (APC) analogs are a novel class of broad-spectrum tumor-targeting agents that can be used for both diagnosis and treatment of cancer. The potential for clinical translation for APC analogs will strongly depend on their pharmacokinetic (PK) profiles. The aim of this work was to understand how the chemical structures of various APC analogs impact binding and PK. To achieve this aim, we performed

Indexed as

Drug DesignMolecular Docking SimulationAnimalsAntineoplastic AgentsHumansLipoproteinsMiceMice, NudeModels, BiologicalNeoplasmsPhosphorylcholineSerum Albumin, HumanAntineoplastic AgentsLipoproteinsPhosphorylcholineSerum Albumin, Humanmodelingmolecular imagingpharmacokineticstheranostics

Identifiers

PMID31082240
PMCPMC6989153
OpenAlexW2945366182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.